A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update
医学
子宫内膜癌
卵巢癌
内科学
肿瘤科
双特异性抗体
抗体
癌症
免疫学
单克隆抗体
作者
Joyce F. Liu,David M. O’Malley,Els Van Nieuwenhuysen,Roisin E. O’Cearbhaill,Sara Bouberhan,Kathleen N. Moore,June Y. Hou,Erika Hamilton,Suk‐Young Yoo,Bin Wang,Mary Peterman,Tamara Schmidt,David A. Knorr,Israel Lowy,Thomas S. Uldrick,Elizabeth Miller
藤椒辣鱼
暴躁的老哥
毛豆
cocolu
归尘
ceeray23
qrwyqjbsd
小红薯7XJ9B2Q4
Cochrane
Yifan2024
Explorer
jyy
SYLH
嗯哼
敬老院1号
sutharsons
小宋
剑指东方是为谁
嘻哈hang
无限面包
皖公网安备34019202002308
